Tuberculosis

Implementation of the culture-based algorithm may have substantially reduced the incidence of tuberculosis (TB) among newly arrived, foreign-born persons in the United States, according to an...  

Mouse studies may lead to development of human therapiesThe cascade of events leading to bacterial infection and the immune response is mostly understood.  

Groundbreaking clinical data published in the The Lancet medical journal showed that reliance on the 100-year-old tuberculin skin test has significantly overestimated latent...  

Controlling the spread of multidrug-resistant tuberculosis (MDR TB) and other infectious diseases is a multi-national problem that requires a multi-national treatment response, a Policy Forum...  

The FDA has cleared the Cepheid Xpert MTB/RIF Assay to help physicians determine if patients with suspected tuberculosis (TB) can be removed from airborne infection isolation.  

Tuberculosis (TB) can be caused by more than one type of bacteria, one of which is Mycobacterium bovis. TB caused by M.  

A CDC analysis of the initial cases leading to 26 tuberculosis (TB) outbreaks in the U.S.  

Normalizing blood vessels within TB lung lesions may increase drug delivery, reduce development of resistanceUse of the same antiangiogenesis drugs that have improved...  

Myriad RBM, a wholly owned subsidiary of Myriad Genetics, Inc. has announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global...  

A new approach to combatting tuberculosis would take advantage of a complex, natural process called autophagy that the human body uses to recycle nutrients, remove damaged cell components, eliminate invading bacteria, and respond to inflammation. In addition to its potential as a novel therapeutic strategy, autophagy is the focus of increasing research to understand the role it may have in a range of diseases including heart disease, diabetes, and age-related neurodegenerative disorders such as Alzheimer's disease.  

Bodies found in a 200 year-old Hungarian crypt have revealed the secrets of how tuberculosis (TB) took hold in 18th century Europe, according to a research team. "Microbiological analyses of samples from contemporary TB patients usually report a single strain of tuberculosis per patient. By contrast, five of the eight bodies in our study yielded more than one type of tuberculosis -- remarkably from one individual we obtained evidence of three distinct strains," one researcher said.  

Cocaine is an illicit drug available as a powder for intranasal or intravenous use or smoked as crack. Short- and long-term use of this drug results in the spread of infectious diseases (for example, AIDS, hepatitis, tuberculosis), crime, violence and prenatal drug exposure. Cocaine dependence is associated with medical and psychosocial complications and is a major public health problem. No proven pharmacological treatment for cocaine dependence is known. Antidepressant, anticonvulsant and dopaminergic medications have all been studied. The present review looked at the efficacy and safety of anticonvulsant drugs for treating cocaine dependence, both as a class and individually.  

We agree that a combination of an interferon γ release assay (IGRA; QuantiFERON-TB Gold in-Tube (QFT-IT) or TSPOT.TB) and a tuberculin skin test is the most sensitive approach to screening for latent tuberculosis infection in patients with rheumatological diseases before starting biological drugs.1  

We agree that a combination of an interferon γ release assay (IGRA; QuantiFERON-TB Gold in-Tube (QFT-IT) or TSPOT.TB) and a tuberculin skin test is the most sensitive approach to screening for latent tuberculosis infection in patients with rheumatological diseases before starting biological drugs.1  

The World Health Organization has rejected an application by Novartis to include ranibizumab (Lucentis) for neovascular eye diseases in the most recent update of its essential medicines list.1 The agency has, however, included “groundbreaking” new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia), and multidrug resistant tuberculosis, among others.  

The World Health Organization has rejected an application by Novartis to include ranibizumab (Lucentis) for neovascular eye diseases in the most recent update of its essential medicines list.1 The agency has, however, included “groundbreaking” new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia), and multidrug resistant tuberculosis, among others.  

The World Health Organization has rejected an application by Novartis to include ranibizumab (Lucentis) for neovascular eye diseases in the most recent update of its essential medicines list.1 The agency has, however, included “groundbreaking” new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia), and multidrug resistant tuberculosis, among others.  

The World Health Organization has rejected an application by Novartis to include ranibizumab (Lucentis) for neovascular eye diseases in the most recent update of its essential medicines list.1 The agency has, however, included “groundbreaking” new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia), and multidrug resistant tuberculosis, among others.  

The World Health Organization has rejected an application by Novartis to include ranibizumab (Lucentis) for neovascular eye diseases in the most recent update of its essential medicines list.1 The agency has, however, included “groundbreaking” new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia), and multidrug resistant tuberculosis, among others.